Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the Scottish Medicine Consortium’s approval of ozanimod for Scottish patients with relapsing remitting multiple sclerosis; and whether it is his policy to provide for the same access to innovative medicines for MS patients in England.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service in England on whether medicines represent a clinical and cost-effective use of resources. NICE’s appraisal of ozanimod for treating relapsing remitting multiple sclerosis is ongoing and a consultation on NICE’s draft guidance closed on 12 February.